Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz Sells 20,000 Shares

Simulations Plus, Inc. (NASDAQ:SLP) Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $31.26, for a total value of $625,200.00. Following the sale, the director now owns 3,481,592 shares of the company’s stock, valued at approximately $108,834,565.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Simulations Plus Stock Down 0.1 %

Shares of SLP stock opened at $30.22 on Friday. The stock has a market cap of $604.64 million, a price-to-earnings ratio of 62.96 and a beta of 0.69. The business’s fifty day moving average is $34.83 and its 200 day moving average is $41.76. Simulations Plus, Inc. has a twelve month low of $29.95 and a twelve month high of $51.22.

Simulations Plus (NASDAQ:SLP) last issued its quarterly earnings results on Tuesday, July 2nd. The technology company reported $0.19 earnings per share for the quarter, topping the consensus estimate of $0.15 by $0.04. The company had revenue of $18.54 million for the quarter, compared to analysts’ expectations of $17.92 million. Simulations Plus had a return on equity of 7.80% and a net margin of 14.36%. The firm’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period in the prior year, the firm earned $0.20 earnings per share. Equities research analysts expect that Simulations Plus, Inc. will post 0.51 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Simulations Plus

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. EntryPoint Capital LLC bought a new position in shares of Simulations Plus during the first quarter valued at $57,000. Allspring Global Investments Holdings LLC bought a new position in shares of Simulations Plus during the first quarter valued at $70,000. Los Angeles Capital Management LLC bought a new position in shares of Simulations Plus during the second quarter valued at $206,000. Arizona State Retirement System bought a new position in shares of Simulations Plus during the second quarter valued at $218,000. Finally, Connecticut Wealth Management LLC bought a new position in shares of Simulations Plus during the first quarter valued at $204,000. 78.08% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. JMP Securities assumed coverage on Simulations Plus in a research report on Tuesday, July 16th. They issued a “market perform” rating for the company. Craig Hallum restated a “buy” rating and issued a $56.00 target price on shares of Simulations Plus in a research report on Wednesday, July 3rd. KeyCorp assumed coverage on Simulations Plus in a research report on Monday, July 29th. They issued an “overweight” rating and a $47.00 target price for the company. William Blair restated an “outperform” rating on shares of Simulations Plus in a research report on Thursday, September 12th. Finally, Oppenheimer boosted their target price on Simulations Plus from $55.00 to $65.00 and gave the stock an “outperform” rating in a research report on Thursday, June 13th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, Simulations Plus has a consensus rating of “Moderate Buy” and a consensus price target of $56.00.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.